Serplulimab in combination with carboplatin and etoposide [SER1]

For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti -cancer therapy with serplulimab in combination with carboplatin and etoposide will be prescribed by a consultant or internally accredited oncology specialty trainee, specifically trained and assessed in the use of systemic anti-cancer therapy.
2. The patient has a histologically or cytologically determined diagnosis of small cell lung cancer (SCLC) and has extensive stage disease.
3. The patient has not received previous systemic therapy for his/her extensive stage disease. Previous treatment with concurrent chemoradiotherapy with / without maintenance durvalumab for limited stage SCLC is allowed as long as therapy was completed at least 6 months prior to the diagnosis of recurrent and extensive stage disease.
4. The patient has an ECOG performance status score of 0 or 1.
5. The patient will be treated with a maximum of four 3-weekly cycles of serplulimab in combination with carboplatin and etoposide.
6. On completion of 4 cycles of serplulimab in combination with carboplatin and etoposide and in the absence of disease progression, treatment with serplulimab maintenance monotherapy will continue until disease progression or symptomatic deterioration or unacceptable toxicity or withdrawal of patient consent, whichever occurs first.
7. Serplulimab will be administered intravenously every 3 weeks.
8. The patient has no symptomatically active brain metastases or leptomeningeal metastases.
9. When a treatment break of more than 12 weeks beyond the expected 3-weekly cycle length is needed, the prescribing clinician will complete a treatment break approval form to restart treatment which must be approved before treatment with serplulimab is re-commenced.
10. Serplulimab, carboplatin and etoposide will be otherwise used as set out in their respective Summary of Product Characteristics (SPCs).

CDF funded From: 29 May 2026 - anticipated to move to NHS funding: 16 September 2026

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.404 of the CDF list, downloaded from NHS England’s website on 30 June 2026 at 14:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.

• SER1_prior_to_cdf_1.404